Ultra-Long-Acting Platform Comprising Fc-Advanced Fatty Acid Chain Extending Drug Half-Life
Summary
The USPTO published patent application US20260097125A1 for an ultra-long-acting drug delivery platform combining immunoglobulin Fc with a modified C14-24 fatty acid chain. The conjugated molecule structure 'active molecule-Fc-Cn' is designed to extend the half-life of therapeutic active molecules. The application was filed on September 22, 2023, with eight inventors including Faming Zhang, Yimin Hu, and colleagues.
What changed
The USPTO published patent application US20260097125A1 disclosing an ultra-long-acting drug delivery platform comprising an active molecule conjugated to immunoglobulin Fc and a modified C14-24 fatty acid chain. The 'active molecule-Fc-Cn' structure aims to improve pharmacokinetics by extending drug half-life through Fc-mediated neonatal Fc receptor (FcRn) recycling combined with fatty acid chain modification.
Pharmaceutical and biotech companies developing therapeutic proteins, peptides, or small molecules requiring extended dosing intervals should review these claims for potential licensing opportunities or competitive implications. The platform's broad applicability to 'any molecules beneficial to an organism' suggests wide potential use across multiple drug classes including GLP-1 analogs, cytokines, and other biologics.
What to do next
- Review patent application claims for freedom-to-operate implications
- Assess Fc-fatty acid conjugation technology for pipeline assets
- Monitor application prosecution for grant or office action
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ULTRA-LONG-ACTING PLATFORM COMPRISING FC-ADVANCED FATTY ACID CHAIN
Application US20260097125A1 Kind: A1 Apr 09, 2026
Inventors
Faming Zhang, Yimin Hu, Yuan Zhou, Yao Yu, Minglong Hu, Xiaolong Wang, Along Zhao, Ying Liang
Abstract
The present invention relates to an ultra-long-acting platform for improving the half-life of an active molecule of a drug, which comprises immunoglobulin Fc and an advanced advanced fatty acid chain. The present invention also relates to preparation of the conjugate platform, a composition comprising the conjugate, and a treatment application thereof. The present invention specifically relates to a conjugated molecule having a structure of “active molecule-Fc-Cn”, wherein the active molecule is selected from any molecules beneficial to an organism, Fc is immunoglobulin IgG Fc, and Cn is a modified moiety comprising a C14-24 fatty acid chain. The present invention also relates to preparation of the conjugated molecule, a composition comprising the conjugate and a treatment application thereof.
CPC Classifications
A61K 47/542 C07K 14/605 C07K 16/22 C07K 16/2818 A61K 38/00 C07K 2319/30
Filing Date
2023-09-22
Application No.
19113341
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.